An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, Phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents - Commentary

Tom Huizinga*, Peter Nigrovic, Eric Ruderman, Hendrik Schulze-Koops

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Number of pages1
JournalInternational Journal of Advances in Rheumatology
Volume9
Issue number2
StatePublished - Dec 1 2011

ASJC Scopus subject areas

  • Rheumatology

Cite this